title: A survey for neutralizing antibodies to the three types of poliovirus among children in Maiduguri, Nigeria.
abstract: The milestone in polio eradication program is to protect effectively children aged 0-5 years against the three serotypes of poliovirus. It became necessary to measure the level of neutralizing antibodies to the three poliovirus types in an endemic State in Nigeria. Neutralizing antibodies to the poliovirus types among children aged 0-5 years was estimated using micro neutralization assay. Of 129 children, 99 (76.8%), 95 (73.6%), and 95 (73.6%) had neutralizing antibodies with the geometric mean titer of 42.7, 31.3, and 33.2 for the poliovirus type 1, 2, and 3, respectively. Fifty-three percent of the children were protected against the three types of poliovirus. Combination of poliovirus types 1 and 2, 1 and 3, and 2 and 3 were neutralized by 62.8, 58.9, and 61.2% of the children studied, respectively. Only poliovirus type 1 induced antibody titres ≥1:1,024. The number of children with neutralizing antibodies after receiving three doses was significantly higher than those who received one or two doses of oral polio vaccine (P ≤ 0.05). However, those who received more than three doses of oral polio vaccine showed no significant difference in their antibody response. The existence of immunity gap poses a risk of re-emergence of the paralytic poliovirus. The existence of unimmunized and unprotected children along with high birth rate could impede the success of polio vaccination in Nigeria. Elimination of non-compliance to polio vaccine, promotion of health education and documented evidence of vaccination of each child with the parents may facilitate the success of polio eradication program in Nigeria.
authors.affiliation: World Health Organization National Polio Laboratory, University of Maiduguri Teaching Hospital, Maiduguri, Nigeria. marycelinb@yahoo.com
authors.forename: M M
authors.initials: MM
authors.lastname: Baba
authors.forename: B A
authors.initials: BA
authors.lastname: Haruna
authors.forename: O
authors.initials: O
authors.lastname: Ogunmola
authors.forename: J P
authors.initials: JP
authors.lastname: Ambe
authors.forename: N N
authors.initials: NN
authors.lastname: Shidali
authors.forename: B
authors.initials: B
authors.lastname: Oderinde
authors.forename: A
authors.initials: A
authors.lastname: Marcello
authors.forename: M
authors.initials: M
authors.lastname: Talle
mesh_terms: D057134:Antibodies, Neutralizing / Q000097:blood*; D000914:Antibodies, Viral / Q000097:blood*; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009500:Neutralization Tests; D009549:Nigeria; D011051:Poliomyelitis / Q000517:prevention & control*; D017955:Poliovirus / Q000276:immunology*; D023321:Poliovirus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D016036:Seroepidemiologic Studies
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D023321:Poliovirus Vaccines